Candel shares fall as operating loss widens and FDA talks continue
Candel Therapeutics shares dropped after a wider operating loss and ongoing talks with the FDA about a license application, per Dow Jones Newswires.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
Shares of biopharmaceutical company Candel Therapeutics slid after it reported a larger operating loss than a year earlier. The company also said it remains in discussions with the US Food and Drug Administration (FDA) about its biologics license application.
According to Dow Jones Newswires, the third-quarter operating loss was $23 million, or 28 cents a share, versus $13.2 million, or 21 cents, a year earlier. Operating expenses nearly doubled, rising to $23 million from $13.2 million.
Candel plans to file the application for aglatimagene in prostate cancer in the middle of 2027, depending on the outcome of those FDA talks. The stock fell 38% to $5.15 in after-hours trading on Thursday, and closed down 9% in the regular session. It is still up 49% this year.
why it matters
For investors, the key issues are spending and the timing of the drug's path to market. Rising costs and a possible delay in filing, after a strong year-to-date run in the shares, make the stock sensitive to regulatory news.
market impact
Candel shares: a wider loss and FDA uncertainty weigh on the stock
- Candel Therapeutics shares pressure down — wider operating loss and uncertainty over the timing of the FDA filing
tags
instruments
sources
- Candel Shares Fall on Wider Loss From Operation, FDA Discussion — Dow Jones Newswires, 12 November 2026 at 23:08 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗